Menu
Search
|

Menu

Close
X

G1 Therapeutics Inc GTHX.OQ (NASDAQ Stock Exchange Global Select Market)

36.85 USD
+0.57 (+1.57%)
As of Sep 17
Previous Close 36.28
Open 35.75
Volume 129,677
3m Avg Volume 151,392
Today’s High 37.39
Today’s Low 34.91
52 Week High 67.95
52 Week Low 13.92
Shares Outstanding (mil) 28.29
Market Capitalization (mil) 731.75
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-1.460
FY18
-2.567
FY17
-2.399
FY16
-1.266
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
5.92
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
0.00
14.55
LT Debt to Equity (MRQ)
vs sector
0.00
10.20
Return on Investment (TTM)
vs sector
--
14.48
Return on Equity (TTM)
vs sector
--
15.78

EXECUTIVE LEADERSHIP

Garry Nicholson
Independent Chairman of the Board, Since 2019
Salary: --
Bonus: --
Mark Velleca
President, Chief Executive Officer, Director, Since 2014
Salary: $515,000.00
Bonus: --
Barclay Phillips
Chief Financial Officer and Senior Vice President - Corporate Development, Since 2017
Salary: $370,000.00
Bonus: $120,000.00
Terry Murdock
Chief Operating Officer, Since 2019
Salary: $351,000.00
Bonus: --
Rajesh Malik
Chief Medical Officer, Senior Vice President - Research and Development, Since 2018
Salary: $336,000.00
Bonus: $67,200.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

79 T.W. Alexander Drive
4501 Research Commons, Suite 100
RESEARCH TRIANGLE PARK   NC   27709

Phone: +1919.2139835

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

SPONSORED STORIES